Evidence map›Paper›PMID 39223207›Full record

ArticleScientific reports2024

Derivation of human primary prostate epithelial cell lines by differentially targeting the CDKN2A locus along with expression of hTERT.

Jason S Wasserman, Holly Fowle, Rumesa Hashmi, Diba Atar, Kishan R Patel, Amir Yarmahmoodi, Alexander W Macfarlane, Yinfei Tan, Edna Cukierman, Bojana Gligorijevic and 4 more

Abstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Jason S Wasserman *Fels Cancer Institute for Personalized Medicine, Temple University Lewis Katz School of Medicine, AHP Bldg., Room 308, 3307 North Broad St., Philadelphia, PA, 19140, USA.
Holly Fowle *Fels Cancer Institute for Personalized Medicine, Temple University Lewis Katz School of Medicine, AHP Bldg., Room 308, 3307 North Broad St., Philadelphia, PA, 19140, USA.
Rumesa Hashmi *Fels Cancer Institute for Personalized Medicine, Temple University Lewis Katz School of Medicine, AHP Bldg., Room 308, 3307 North Broad St., Philadelphia, PA, 19140, USA.
Diba Atar *Fels Cancer Institute for Personalized Medicine, Temple University Lewis Katz School of Medicine, AHP Bldg., Room 308, 3307 North Broad St., Philadelphia, PA, 19140, USA.
Kishan R PatelFels Cancer Institute for Personalized Medicine, Temple University Lewis Katz School of Medicine, AHP Bldg., Room 308, 3307 North Broad St., Philadelphia, PA, 19140, USA.
Amir YarmahmoodiTemple University Lewis Katz School of Medicine, Philadelphia, PA, USA.
Alexander W MacfarlaneInstitute for Cancer Research, Cancer Signaling and Microenvironment Program, Fox Chase Cancer Center, Philadelphia, USA.
Yinfei TanInstitute for Cancer Research, Cancer Signaling and Microenvironment Program, Fox Chase Cancer Center, Philadelphia, USA.
Edna CukiermanTemple University Lewis Katz School of Medicine, Philadelphia, PA, USA.
Bojana GligorijevicFels Cancer Institute for Personalized Medicine, Temple University Lewis Katz School of Medicine, AHP Bldg., Room 308, 3307 North Broad St., Philadelphia, PA, 19140, USA.
Adam KaramiFels Cancer Institute for Personalized Medicine, Temple University Lewis Katz School of Medicine, AHP Bldg., Room 308, 3307 North Broad St., Philadelphia, PA, 19140, USA.
Kelly A WhelanFels Cancer Institute for Personalized Medicine, Temple University Lewis Katz School of Medicine, AHP Bldg., Room 308, 3307 North Broad St., Philadelphia, PA, 19140, USA.
Kerry S CampbellTemple University Lewis Katz School of Medicine, Philadelphia, PA, USA.
Xavier GrañaFels Cancer Institute for Personalized Medicine, Temple University Lewis Katz School of Medicine, AHP Bldg., Room 308, 3307 North Broad St., Philadelphia, PA, 19140, USA. xgrana@temple.edu.

Funding

WORD PROCESSING CENTER--COREP30CA006927 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI Eric Andrew Ross · 1985 to 2026
$138.8M
TUFCCC/HC Regional Comprehensive Cancer Health PartnershipU54CA221704 · NCI · HUNTER COLLEGE · PI Ming-Chin Yeh · 2018 to 2026
$10.6M
Pancreatic Cancer-Associated Fibroblasts: Function, Detection, and RegulationR01CA269660 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI Edna Cukierman · 2022 to 2026
$3.1M
Targeting invadopodia-related mechanisms of cancer cell invasion and metastasisR01CA230777 · NCI · TEMPLE UNIV OF THE COMMONWEALTH · PI GLIGORIJEVIC, BOJANA · 2019 to 2023
$1.9M
Unraveling the complexity of substrate specificity of PP2A/B55a, a major eukaryote Serine/Threonine PhosphataseR01GM117437 · NIGMS · TEMPLE UNIV OF THE COMMONWEALTH · PI GRANA, XAVIER · 2016 to 2019
$1.3M
PPP2R2A tumor suppression haploinsufficiency in prostate cancerR03CA216134 · NCI · TEMPLE UNIV OF THE COMMONWEALTH · PI GRANA, XAVIER · 2017 to 2018
$159k
NCI NIH HHS P30 CA006927NCI NIH HHS P30CA006927NCI NIH HHS Pre-Pilot Award from U54 CA221704NCI NIH HHS R01 CA230777NCI NIH HHS R01 CA269660NCI NIH HHS R03 CA216134NCI NIH HHS R03 CA216134-01NCI NIH HHS U54 CA221704NIGMS NIH HHS R01 GM117437
6 · The paper itself

Abstract

Prostate cancer (PCa) is the most common cancer diagnosed in men worldwide and was the second leading cause of cancer-related deaths in US males in 2022. Prostate cancer also represents the second highest cancer mortality disparity between non-Hispanic blacks and whites. However, there is a relatively small number of prostate normal and cancer cell lines compared to other cancers. To identify the molecular basis of PCa progression, it is important to have prostate epithelial cell (PrEC) lines as karyotypically normal as possible. Our lab recently developed a novel methodology for the rapid and efficient immortalization of normal human PrEC that combines simultaneous CRISPR-directed inactivation of CDKN2A exon 2 (which directs expression of p16

Indexed as

Cyclin-Dependent Kinase Inhibitor p16Epithelial CellsProstateProstatic NeoplasmsTelomeraseCell LineCell Line, TumorExonsGene Expression Regulation, NeoplasticHumansMaleCDKN2A protein, humanCyclin-Dependent Kinase Inhibitor p16TelomeraseTERT protein, human

Identifiers

PMID39223207
PMCPMC11369182

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.